The most recent studies [124,125,126,127] have revealed that the combination of neoadjuvant pertuzumab and trastuzumab alongside chemotherapy leads to elevated rates of pathological complete response (pCR) in real-world patients with HER2-positive early breast cancer, demonstrating a satisfactory safety record. The gene discussed is ERBB2; the disease is breast carcinoma.